Recommendations for the use of bioresorbable vascular scaffolds in percutaneous coronary interventions

• DOI: 10.1007/s12471-017-1014-z
• Publication Date: 2017-06-22T02:11:20Z
• Authors: B. Everaert; J. J. Wykrzykowska; J. Koolen; P. van der Harst; P. den Heijer; J. P. Henriques; R. van der Schaaf; B. de Smet; S. H. Hofma; R. Diletti; A. Weevers; J. Hoorntje; P. Smits; R. J. van Geuns
• Keywords: Bare metal

To eliminate some of the potential late limitations permanent metallic stents, bioresorbable coronary stents or 'bioresorbable vascular scaffolds' (BVS) have been developed. We reviewed all currently available clinical data on BVS implantation. Since 2015 position statement appropriateness in percutaneous interventions, several large randomised trials presented. These demonstrated that achieving adequate 1 and 2 year outcomes with these first-generation is not straightforward. first adequately powered studies non-complex lesions showed worse results if standard implantation techniques were used for relatively thick scaffolds. Post-hoc analyses hypothesise similar to current drug-eluting are still possible aggressive lesion preparation, sizing high-pressure postdilatation implemented rigorously. As long as this has confirmed prospective usage should be restricted experienced centres continuous outcome monitoring. For more complex lesions, even disappointing discouraged. When developed, newer generation scaffolds thinner struts faster resorption rates expected improve outcomes. In meantime prolonged dual antiplatelet therapy (DAPT, beyond one year) recommended an individualised approach patients treated BVS. The new 2017 recommendations downgrade limit use within dedicated registries using updated protocol advise DAPT. line manufacturer does supply devices hospitals without such place.